SLCO1B1 gene single nucleotide polymorphism is a drug response marker for pancreatic cancer patients treated with gemcitabine

被引：0
|
作者：
Ueno, H. [1 ]
Ioka, T. [2 ]
Ohkawa, S. [3 ]
Ikeda, M. [4 ]
Shimamura, T. [5 ]
Tsuji, A. [6 ]
Tsuchiya, Y. [7 ]
Okusaka, T. [1 ]
Yoshida, T. [8 ]
Sato, Y. [9 ]
机构：
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Oncol Div, Tokyo, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Div Hepatobiliary & Pancreat Oncol, Osaka, Japan
[3] Kanagawa Canc Ctr, Div Gastroenterol, Kawasaki, Kanagawa, Japan
[4] Natl Canc Ctr Hosp East, Div Hepatobiliary & Pancreat Oncol, Chiba, Japan
[5] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[6] Kochi Hlth Sci Ctr, Dept Clin Oncol, Kochi, Japan
[7] Niigata Canc Ctr Hosp, Div Surg, Niigata, Japan
[8] Natl Canc Ctr, Div Genet, Tokyo, Japan
[9] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2582
引用
收藏
页码：S613 / S613
页数：1
相关论文
共 50 条
  • [41] Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism
    Kalliokoski, A.
    Backman, J. T.
    Kurkinen, K. J.
    Neuvonen, P. J.
    Niemi, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (04) : 488 - 496
  • [42] Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    Kalliokoski, Annikka
    Neuvonen, Mikko
    Neuvornen, Pertti J.
    Niemi, Mikko
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (03): : 311 - 321
  • [43] SLCO1B1 TRANSPORTER POLYMORPHISM IS NOT ASSOCIATED WITH RISK OF MYOPATHY IN CZECH POPULATION
    Hubacek, J. A.
    Dlouha, D.
    Adamkova, V.
    Ceska, R.
    Vrablik, M.
    ATHEROSCLEROSIS, 2014, 235 (02) : E256 - E256
  • [44] Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
    Suwannakul, Suttasinee
    Ieiri, Ichiro
    Kimura, Miyuki
    Kawabata, Kiyoshi
    Kusuhara, Hiroyuki
    Hirota, Takeshi
    Irie, Shin
    Sugiyama, Yuichi
    Higuchi, Shun
    JOURNAL OF HUMAN GENETICS, 2008, 53 (10) : 899 - 904
  • [45] SLCO1B1 and SLCO1B3 genetic mutations in Taiwanese patients with Rotor syndrome
    Cheng, Ya-Yuan
    Chang, Kai -Chi
    Chen, Pei -Lung
    Yeung, Chun-Yan
    Liou, Bang -Yu
    Chen, Huey -Ling
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (07) : 648 - 652
  • [46] Effect of SLCO1B1 Polymorphism on Plasma Bile Acid Concentrations in Humans
    Xiang, Xiaoqiang
    Han, Yi
    Neuvonen, Mikko
    Pasanen, Marja K.
    Kalliokoski, Annikka
    Backman, Janne T.
    Laitila, Jouko
    Neuvonen, Pertti J.
    Niemi, Mikko
    DRUG METABOLISM REVIEWS, 2009, 41 : 77 - 77
  • [47] Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
    Suttasinee Suwannakul
    Ichiro Ieiri
    Miyuki Kimura
    Kiyoshi Kawabata
    Hiroyuki Kusuhara
    Takeshi Hirota
    Shin Irie
    Yuichi Sugiyama
    Shun Higuchi
    Journal of Human Genetics, 2008, 53 : 899 - 904
  • [48] The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics is independent of repaglinide dose
    Kalliokoski, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 24 - 24
  • [49] Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban
    Han, Ji Min
    Jang, Eun Jeong
    Yee, Jeong
    Song, Tae-Jin
    Kim, Dong-Hyeok
    Park, Junbeom
    Gwak, Hye Sun
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [50] Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban
    Ji Min Han
    Eun Jeong Jang
    Jeong Yee
    Tae-Jin Song
    Dong-Hyeok Kim
    Junbeom Park
    Hye Sun Gwak
    Scientific Reports, 13 (1)
12345